...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Cytokine >CXCL12 rs1801157 polymorphism and expression in peripheral blood from breast cancer patients.
【24h】

CXCL12 rs1801157 polymorphism and expression in peripheral blood from breast cancer patients.

机译：CXCL12 rs1801157多态性与乳腺癌患者外周血中的表达。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

The role of chemokines has been extensively analyzed both in cancer risk and tumor progression. Among different cytokines, CXCR4 and its ligand CXCL12 have been recently subjected to a closer examination. The single-nucleotide polymorphism (SNP) rs1801157 (previously known as CXCL12-A/SDF1-3'A) in the CXCL12 gene and the relative expression of mRNA CXCL12 in peripheral blood were assessed in breast cancer patients, since the chemokine CXCL12 and its receptor CXCR4 regulate leukocyte trafficking and many essential biological processes, including tumor growth, angiogenesis and metastasis of different types of tumors. Genotyping was performed by PCR-RFLP (polymerase chain reaction followed by restriction fragment length polymorphism) using MspI restriction enzyme and the expression analyses by quantitative RT-PCR. No difference in GG genotype and allele A carrier frequencies were observed between breast cancer patients and healthy blood donors and nor when CXCL12 mRNA expression was assessed among patients with different tumor stages. However a significant difference was observed when CXCL12 mRNA relative expression was analyzed in breast cancer patients in accordance to the presence or absence of the CXCL12 rs1801157 allele A. Allele A breast cancer patients presented a mRNA CXCL12 expression about 2.1-fold smaller than GG breast cancer patients. Estrogen positive patients presenting CXCL12 allele A presented a significantly lower expression of CXCL12 in peripheral blood (p=0.039) than GG hormone positive patients. Our findings demonstrated that allele A is associated with low expression of CXCL12 in the peripheral blood from ER-positive breast cancer patients, which suggests implications on breast cancer clinical outcome.
机译：趋化因子在癌症风险和肿瘤进展中的作用已得到广泛分析。在不同的细胞因子中，最近对CXCR4及其配体CXCL12进行了仔细检查。由于趋化因子CXCL12及其化学成分在乳腺癌患者中被评估了CXCL12基因中的单核苷酸多态性（SNP）rs1801157（以前称为CXCL12-A / SDF1-3'A）和外周血中mRNA CXCL12的相对表达。受体CXCR4调节白细胞运输和许多必不可少的生物学过程，包括肿瘤生长，血管生成和不同类型肿瘤的转移。使用MspI限制酶，通过PCR-RFLP（聚合酶链反应，然后进行限制片段长度多态性）进行基因分型，并通过定量RT-PCR进行表达分析。在乳腺癌患者和健康献血者之间未观察到GG基因型和等位基因A携带者频率的差异，并且在不同肿瘤阶段的患者之间未评估CXCL12 mRNA的表达。但是，根据是否存在CXCL12 rs1801157等位基因A在乳腺癌患者中分析CXCL12 mRNA相对表达时，观察到显着差异。等位基因A乳腺癌患者的mRNA CXCL12表达比GG乳腺癌小2.1倍耐心。呈现CXCL12等位基因A的雌激素阳性患者比GG激素阳性患者的外周血CXCL12表达显着降低（p = 0.039）。我们的研究结果表明，等位基因A与ER阳性乳腺癌患者外周血中CXCL12的低表达有关，这暗示了对乳腺癌临床结果的影响。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号